Skip to main content
. 2005 Oct 26;92(7):951–957. doi: 10.1136/hrt.2005.074716

Table 1 Clinical characteristics of the study patients.

Total population (n = 76) Conventional group (n = 38) Thrombectomy group (n = 38)
Age (years) 65.3 (11.2) 64.6 (12.5) 66.7 (14.1)
Men 48 (63.1%) 21 (55.3%) 27 (71%)
Risk factors
 Hypertension 34 (44.7%) 19 (50%) 15 (39.5%)
 Diabetes 16 (21%) 7 (18.4%) 9 (23.7%)
 Smoking 17 (22.4%) 10 (26.3%) 7 (18.4%)
 Obesity 4 (5.3) 1 (2.6) 3 (7.9)
 Family history of CAD 19 (25%) 14 (36.8%) 5 (13.1%)*
 Cholesterol (mmol/l) 4.22 (0.70) 4.32 (0.39) 4.17 (0.28)*
 Triglycerides (mmol/l) 1.38 (0.42) 1.41 (0.29) 1.37 (0.44)
Renal failure 8 (10.5%) 3 (7.9%) 5 (13.1%)
Killip class III 19 (25%) 11 (28.9%) 8 (21%)
Previous PCI 11 (14.5%) 4 (10.5%) 7 (18.4%)
Symptoms to balloon (hours) 7.3 (1.3) 7.6 (1.8) 7.2 (1.9)
Medications at follow up
 ACE‐I/ARBs 67 (88.1%) 31 (81.6%) 36 (94.7%)
 Aldosterone blockers 41 (53.9%) 22 (57.9%) 19 (50%)
 β Blockers 58 (76.3%) 27 (71%) 31 (81.6%)
 Statins 68 (89.5%) 36 (94.7%) 32 (84.2%)
 Aspirin 74 (97.4%) 37 (97.4%) 37 (97.4%)

Data are mean (SD) or number (%).

*p<0.05 between conventional and thrombectomy groups.

ACE‐I, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CAD, coronary artery disease; PCI, percutaneous coronary angioplasty.